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Objective: The very low-density lipoprotein receptor (VLDLR) plays an important role in the development of hepatic steatosis. In this study, we
investigated the role of Peroxisome Proliferator-Activated Receptor (PPAR)b/d and ﬁbroblast growth factor 21 (FGF21) in hepatic VLDLR
regulation.
Methods: Studies were conducted in wild-type and Pparb/d-null mice, primary mouse hepatocytes, human Huh-7 hepatocytes, and liver
biopsies from control subjects and patients with moderate and severe hepatic steatosis.
Results: Increased VLDLR levels were observed in liver of Pparb/d-null mice and in Pparb/d-knocked down mouse primary hepatocytes through
mechanisms involving the heme-regulated eukaryotic translation initiation factor 2a (eIF2a) kinase (HRI), activating transcription factor (ATF) 4
and the oxidative stress-induced nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways. Moreover, by using a neutralizing antibody against
FGF21, Fgf21-null mice and by treating mice with recombinant FGF21, we show that FGF21 may protect against hepatic steatosis by attenuating
endoplasmic reticulum (ER) stress-induced VLDLR upregulation. Finally, in liver biopsies from patients with moderate and severe hepatic
steatosis, we observed an increase in VLDLR levels that was accompanied by a reduction in PPARb/d mRNA abundance and DNA-binding activity
compared with control subjects.
Conclusions: Overall, these ﬁndings provide new mechanisms by which PPARb/d and FGF21 regulate VLDLR levels and inﬂuence hepatic
steatosis development.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Original Articlean important risk factor for the development of obesity-related pa-
thologies including insulin resistance, type 2 diabetes mellitus (T2DM),
and cardiovascular diseases [2].
Hepatic triglyceride levels are regulated by multiple mechanisms such
as de novo synthesis, fatty acid oxidation, lipolysis, dietary fat con-
sumption, and the secretion and hepatic delivery of lipoprotein parti-
cles [3e5]. Recently, it has been reported that very low-density
lipoprotein receptor (VLDLR) plays an important role in the develop-
ment of hepatic steatosis [6]. VLDLR belongs to the low-density lipo-
protein (LDL) receptor family and is widely expressed in the brain,
heart, skeletal muscle, and adipose tissue, whereas its expression is
very low in the liver under normal conditions [7,8]. This receptor binds
apolipoprotein E (apoE) triglyceride-rich lipoproteins such as chylo-
microns, VLDL, and intermediate density lipoproteins, leading to lipid
entry into the cell through lipoprotein lipase (LPL)-dependent lipolysis
or receptor-mediated endocytosis [9e12]. As a result, a link has been
established between VLDLR levels and plasma triglyceride levels [13].
VLDLR-null mice are leaner, display normal blood lipids [14] and are
protected from obesity induced by HFD feeding or leptin deﬁciency
[15]. However, following fasting or exposure to a HFD, these animals
show increased plasma triglyceride levels [15,16]. In recent years, it
has been reported that VLDLR is regulated by several transcription
factors, including Peroxisome Proliferator-Activated Receptor (PPAR) g
in adipose tissue [12] and hypoxia-inducible factor 1a (HIF-1a) in the
heart [17], contributing to lipid deposition in both tissues. In liver, the
upregulation of VLDLR levels has been reported to be dependent on the
activation of oxidative stress-induced nuclear factor (erythroid-derived
2)-like 2 (Nrf2) in alcoholic liver disease [18], whereas stimulation of
activating transcription factor 4 (ATF4) signaling during endoplasmic
reticulum (ER) stress induces hepatic steatosis via increase VLDLR by
enhancing lipoprotein delivery to the liver [6]. In addition, hepatic
VLDLR upregulation plays an essential role in the triglyceride-lowering
effect of fenoﬁbrate through PPARa activation [19]. However, little is
known about the effects of PPARb/d on VLDLR regulation in the liver.
PPARb/d is a ligand-activated transcription factor involved in the
regulation of glucose and lipid homeostasis [20], and it has been
proposed as a therapeutic target for the treatment of metabolic syn-
drome [21]. Thus, genetic manipulation of PPARb/d as well as its
activation by agonists attenuate dyslipidemia and hyperglycemia,
improve whole-body insulin sensitivity, and prevent diet-induced
obesity [22]. In this study, we show that Pparb/d deﬁciency regu-
lates VLDLR levels through Nrf2 and ATF4-dependent mechanisms,
whereas ﬁbroblast growth factor 21 (FGF21) deﬁciency exacerbates ER
stress-induced VLDLR levels, contributing to the progression of hepatic
steatosis. Finally, our ﬁndings show that in humans with severe he-
patic steatosis, increased levels of VLDLR accompany a reduction in
PPARb/d activity.
2. RESEARCH DESIGN AND METHODS
2.1. Reagents
Control, VLDLR, HRI, ATF4, and Nrf2 siRNA were purchased from Santa
Cruz (Dallas, TX) and PPARb/d siRNA from GE Dharmacon (Lafayette,
CO). Mouse FGF21 neutralizing antibody was purchased from Antibody
and Immunoassays Services (Hong Kong, China) and human recom-
binant FGF21 from R&D Systems (Minneapolis, MN). Triglyceride levels
were measured using a commercial kit (Sigma, St. Louis, MO).
2.2. Mice
Male (8e9-wk old) Pparb/d knockout (Pparb/d/) mice and their
wild-type littermates (Pparb/dþ/þ) with the same genetic background118 MOLECULAR METABOLISM 8 (2018) 117e131  2017 The Authors. Published by Elsevier GmbH. T(C57BL/6X129/SV) [23] and an initial weight of 20e25 g were fed a
standard diet. Genotyping was performed as previously described [23].
Wild-type and Pparb/d-null mice were treated for 24 h through i.p.
injection with DMSO (vehicle) or tunicamycin (3 mg kg1 body weight).
Likewise, male wild-type and Pparb/d-null mice at 12 wk. of age were
injected intraperitoneally with IgG (9 mg/mouse) or a neutralizing
antibody (9 mg/mouse) against FGF21 [24] together with DMSO or
tunicamycin (3 mg kg1 body weight) and were sacriﬁced at 14 h after
treatment. In addition, male wild-type and Pparb/d-null mice were
either fed a 30% fructose solution or plain tap water for 12 wk, as
previously described [25]. The hepatic content of malondialdehyde
(MDA) and hydrogen peroxide (H2O2) were determined using the lipid
peroxidation (MDA) and Peroxidetect assay kits (Sigma), respectively.
Male (10-wk old) knockout (Fgf21/) mice [B6N; 129S5-Fgf21tm1Lex/
Mmcd] and their wild-type littermates (Fgf21þ/þ) were obtained from
the Mutant Mouse Regional Resource Center (MMRRC). For exami-
nation of the effect of FGF21 on VLDLR levels, male C57BL/6 mice at
12 wk of age were treated with DMSO or tunicamycin (1 mg kg1 body
weight), and starting at 6 h before tunicamycin injection, recombinant
mouse FGF21 (PeproTech, London, UK) was administered intraperi-
toneally at 1 mg kg1 body weight for a total of ﬁve times every 6 h.
Mice were sacriﬁced at 24 h after tunicamycin treatment. All animals
were killed under anesthetic conditions, and livers were snap-frozen in
liquid nitrogen immediately after resection and stored at 80 C. The
research complied with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publi-
cation No. 85-23, revised 1996). All procedures were approved by the
University of Barcelona Bioethics Committee, as stated in Law 5/21
July 1995 passed by the Generalitat de Catalunya.
2.3. Cell culture
Human Huh-7 cells (a kindly gift from Dr. Mayka Sanchez from Josep
Carreras Leukaemia Research Institute) were cultured in DMEM sup-
plemented with 10% serum, at 37 C/5% CO2. Primary mouse he-
patocytes were isolated from non-fasting male C57BL/6 mice (10e12
weeks old) by perfusion with collagenase as described elsewhere [26].
siRNA transfections were performed with Lipofectamine 2000 (Life
Technologies).
2.4. Human samples
Subjects were recruited by the Gastroenterology Department at the
Shahid Beheshti University of Medical Sciences (Tehran, Iran) with
the approval of the Ethical Committee of the University Review Board
of the participating Taleghani Hospital. NAFLD subjects (Table S1)
were diagnosed according to WHO criteria. Patients were considered
as having potential liver steatosis if they had abnormal liver blood
tests. Alcohol consumption had to be less than 20 g/day for the past
5 years, as assessed using a standard questionnaire. In addition, liver
specimen had to be compatible with NAFLD [27], without any pattern
suggestive of other cause. Patients were not included if they had
another cause of chronic liver disease, complicated cirrhosis, or
received putative antiﬁbrotic treatment in the past 6 months. Liver
biopsies were performed at Taleghani Hospital in 2012e2013 using
a Meghini 16 swg (1.6 mm)  70 mm syringe. The material con-
sisted of 15 needle biopsies from adult patients. Specimens were
immediately sent for pathology assessment by routine procedures;
two biopsies were required to obtain an acceptable specimen. All the
biopsies were reviewed by the pathologist and the presence of
steatosis was graded in grade 0 with <5% of hepatocytes presenting
steatosis (control group) (n ¼ 5), grade 2 with 33e66% of hepa-
tocytes presenting steatosis (n ¼ 4), and grade 3 with more thanhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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66% steatotic hepatocytes (n ¼ 6). Written informed consent was
obtained from each patient included in the study and the study
protocol conformed to the ethical guidelines of the 2013 Declaration
of Helsinki as reﬂected in a priori approval by the institution’s human
research committee.
2.5. RNA preparation and quantitative RT-PCR
The relative levels of speciﬁc mRNAs were assessed by Real-Time
RT-PCR, as previously described [28]. Primer sequences used for
Real-Time RT-PCR are displayed in Table S2.
2.6. Immunoblotting
Isolation of total and nuclear extracts was performed as described
elsewhere [28]. Proteins (30 mg) were separated by SDS-PAGE on 10%
acrylamide separation gels and transferred to Immobilon poly-
vinylidene diﬂuoride membranes (Millipore). Western blot analysis was
performed using antibodies against VLDLR (sc-18824), Nrf2 (sc-722),
Nqo1 (sc-393736), ATF4 (sc-200) (Santa Cruz), VLDLR (AF2258) (R&D
system), eIF2a (9722), phospho-eIF2a (Ser51) (9721), IgG control
(2729S) (Cell Signaling Technology Inc., Danvers, MA), actin (A5441)
(SigmaeAldrich, Madrid, Spain). Detection was achieved using the
Western Lightning Plus-ECL chemiluminescence kit (PerkinElmer,
Waltham, MA, USA). The equal loading of proteins was assessed by
Ponceau S staining. The size of detected proteins was estimated using
protein molecular-mass standards (Bio-Rad).
2.7. Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was performed using
double-stranded oligonucleotide for the consensus binding site of
PPRE (Santa Cruz Biotechnology). Nuclear extracts (NE) were isolated
as previously reported [28]. Oligonucleotides were labeled by incu-
bating the following reaction at 37 C for 2 h: 2 mL oligonucleotide
(1.75 pmol/mL), 2 mL of 5X kinase buffer, 1 mL of T4 polynucleotide
kinase (10 U/mL), and 2.5 mL [g-32P] ATP (3,000 Ci/mmol at 10 mCi/
mL). The reaction was stopped by adding 90 mL of TE buffer (10 mmol/
L TriseHCl, pH 7.4, and 1 mmol/L EDTA). To separate the labeled
probe from the unbound ATP, the reaction mixture was eluted in a Nick
column (GE Healthcare, Barcelona, Spain) according to the manufac-
turer’s instructions. Five micrograms of crude nuclear protein was
incubated for 10 min on ice in binding buffer (10 mmol/L TriseHCl, pH
8.0, 25 mmol/L KCl, 0.5 mmol/L dithiothreitol, 0.1 mmol/L EDTA, pH
8.0, 5% (v:v) glycerol, 5 mg/mL BSA, and 50 mg/ml poly[dI-dC]) in a
ﬁnal volume of 15 mL. Then, speciﬁc competitor oligonucleotide or
antibody for supershift assays were added and incubated for 15 min on
ice. Subsequently, the labeled probe (100,000 cpm) was added and
the reaction was incubated for an additional 15 min on ice. Finally,
protein-DNA complexes were resolved by electrophoresis at 4 C on
5% (w:v) polyacrylamide gels in 0.5X Tris-borate-EDTA buffer and
subjected to autoradiography.
2.8. Hematoxylin-eosin and Oil Red and staining
We performed hematoxylin-eosin and Oil Red O staining as previously
reported [28]. ORO staining was quantiﬁed using Image J software.
2.9. Statistical analyses
Results are expressed as means  S.D. Signiﬁcant differences were
established by two-way ANOVA using the GraphPad Instat program
(GraphPad Software V5.01) (GraphPad Software Inc., San Diego, CA).
When signiﬁcant variations were found by two-way ANOVA, the
TukeyeKramer multiple comparison post-test was performed. Dif-
ferences were considered signiﬁcant at p < 0.05.MOLECULAR METABOLISM 8 (2018) 117e131  2017 The Authors. Published by Elsevier GmbH. This is an op
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3.1. Pparb/d/e mice show increased hepatic VLDLR levels
First, we examined whether Pparb/d-deﬁciency affected VLDLR levels.
VLDLR mRNA and protein levels were increased in the livers of Pparb/
d/ mice compared with wild-type littermates (Figure 1A and B). This
increase in VLDLR was accompanied by the presence of hepatic
steatosis in Pparb/d/ mice compared to wild-type littermates, as
demonstrated by ORO and hematoxylin-eosin staining and hepatic
triglyceride quantiﬁcation (Figure 1C and D), whereas differences in
plasma triglyceride levels did not reach statistical signiﬁcance (data not
shown). In accordance with the observations in the liver of Pparb/d-
deﬁcient mice, siRNA knockdown of Pparb/d in primary hepatocytes
(Figure S1B) led to enhanced Vldlr mRNA and protein levels (Figure 1E
and F). Similarly, transfection of human Huh-7 hepatocytes with siRNA
against PPARb/d caused a signiﬁcant increase in VLDLR mRNA levels
(Figure 1G) and in cellular lipid accumulation (Figure 1H). Next, we
focused on ATF4 as the potential transcription factor responsible for
the increase in VLDLR in Pparb/d-deﬁcient cells. Although ATF4 is
activated by ER stress through eukaryotic translation initiation factor
2a (eIF2a), the increase in phosphorylated eIF2a and activation of its
downstream ATF4 signaling pathway can occur independently of ER
stress, since eIF2a can also be phosphorylated by other kinases,
including the heme-regulated eIF2a kinase (HRI) [29]. Interestingly,
Pparb/d/ mice showed increased levels of HRI, which in turn ac-
tivates the eIF2a-ATF4 pathway [28], suggesting that HRI might also
regulate VLDLR levels. In agreement with this, siRNA knockdown of Hri
(Figure S1A) in primary hepatocytes caused a reduction in VLDLR
mRNA and protein levels (Figure 2A). Moreover, two well-known HRI
activators [30], BTCtFPU and BTdCPU, upregulated VLDLR mRNA and
protein levels in human Huh-7 hepatocytes (Figure 2B), and BTdCPU
also upregulated VLDLR levels in the liver of mice treated with this
compound (Figure 2C).
Next, we checked whether other transcription factors such as Nrf2,
known to be involved in the upregulation of hepatic VLDLR [18], might
be responsible for the increase in the expression of this gene in the
livers of Pparb/d-null mice. Interestingly, livers of Pparb/d/ mice
showed increased levels of phosphorylated Nrf2, an indicator of the
activity of this transcription factor [31], compared with wild-type lit-
termates (Figure 2D). In agreement with this, the mRNA and protein
levels of the Nrf2-target gene NAD(P)H quinone dehydrogenase 1
(Nqo1) were also upregulated (Figure 2D and E).
To conﬁrm the involvement of HRI, ATF4, and Nrf2 in the upregulation
of Vldlr in the context of Pparb/d deﬁciency, we performed siRNA
studies in primary hepatocytes. Knockdown of Pparb/d increased the
expression of Vldlr, but this increase was prevented by siRNA trans-
fection against Atf4, Nrf2, or Hri (Figure 2F). Two ATF4-target genes,
Trb3 [28] and Fgf21 [32], were upregulated by Pparb/d knockdown,
but this was prevented by transfecting siRNA against either Atf4 or Hri
(Figure S1C and D). Similarly, expression of Nrf2 and two of its target
genes, Nqo1 and Ho-1, increased following Pparb/d knockdown and
this was prevented by siRNA transfection against Nrf2 (Figure S1EeG).
These ﬁndings indicate that Pparb/d deﬁciency increases Vldlr
expression through the HRI-eIF2a-ATF4 and Nrf2 pathways.
3.2. Pparb/d deﬁciency exacerbates hepatic steatosis and VLDLR
upregulation caused by ER stress
Given that ER stress induces hepatic steatosis via increased expression
of VLDLR through eIF2a-ATF4 [6], we hypothesized that Pparb/d
deﬁciency may exacerbate liver steatosis in the context of ER stress by
potentiating the increase in VLDLR levels. To test this, wild-type anden access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 119
Figure 1: VLDLR abundance is increased in liver of Pparb/d-null mice and in primary hepatocytes following knockdown of Pparb/d. Livers from male wild-type (WT) and
Pparb/d-null mice were used (n ¼ 6 per group). A, Assessment by quantitative real-time RT-PCR of hepatic Vldlr. B, Immunoblot analysis of liver VLDLR. C, Oil Red O and
hematoxylin-eosin staining of livers. Scale bar: 100 mm. D, Liver triglyceride levels. Data are presented as the mean  S.D. (n ¼ 6 per group) relative to the wild-type mice. Vldl
mRNA abundance (E) and protein levels (F) in primary hepatocytes transfected with control siRNA or Pparb/d siRNA for 24 h. VLDLR mRNA levels (G) and Oil Red O staining (H) in
Huh-7 hepatocytes transfected with control siRNA or Pparb/d siRNA for 24 h. Levels are presented as the mean  S.D. (n ¼ 3e5 per group). *p < 0.05 vs. wild-type mice o
control siRNA. Scale bar: 100 mm.
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Figure 2: HRI regulates VLDLR abundance in hepatocytes. A, primary hepatocytes were transfected with control or Hri siRNA for 24 h, and the mRNA abundance and protein
levels of VLDLR were assessed. *p < 0.05 and **p < 0.01 vs. control siRNA. B, Huh-7 hepatocytes were incubated for 16 h in the absence (Control, CT) or presence of 10 mmol/L of
either BTdCPU or BTCtFPU and the mRNA abundance and protein levels of VLDLR were analyzed. ***p < 0.001, **p < 0.01 and *p < 0.05 vs. control. C, mRNA abundance and
protein levels of VLDLR in liver of mice treated with DMSO (vehicle) or BTdCPU (70 mg kg1 day1) for 7 days (n ¼ 6 per group). ***p < 0.001, **p < 0.01 and *p < 0.05 vs.
control cells or control mice. Immunoblot analyses of total and phospho-Nrf2 and NQO1 (D) and mRNA abundance of Nqo1 (E) in liver from male wild-type (WT) and Pparb/d-null
mice (n ¼ 6 per group). *p < 0.05 vs. control. F, VLDLR mRNA abundance in primary hepatocytes transfected with control, Ppard, Atf4, Nrf2 and Hri siRNA for 24 h *p < 0.05 vs.
control siRNA. #p < 0.05 vs. Ppard siRNA.
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Original ArticlePparb/d/ mice were treated with the ER stressor tunicamycin for
24 h. Tunicamycin increased hepatic triglyceride accumulation in wild-
type mice (approximately 5-fold increase, p < 0.01) compared with
vehicle-treated animals, but this accumulation was exacerbated in
tunicamycin-treated Pparb/d/ mice (approximately 8-fold increase,
p < 0.001 compared with tunicamycin-treated wild-type mice)
(Figure 3AeC). In agreement with an increased lipoprotein delivery to
the liver through VLDLR as the mechanism responsible for hepatic
steatosis, plasma triglyceride levels were reduced in tunicamycin-
treated wild-type mice (60% reduction, p < 0.01) compared with
vehicle-treated wild-type mice. This reduction was exacerbated in
tunicamycin-treated Pparb/d/ mice (70% reduction, p < 0.001)
compared with vehicle-treated Pparb/d/ mice (Figure 3D), which is
consistent with the higher increase in VLDLR protein levels in the livers
of tunicamycin-treated Pparb/d/ mice (Figure 3E). Likewise, the
expression of two additional ATF4-target genes, Trb3 and Chop, was
signiﬁcantly higher in tunicamycin-treated Pparb/d/ mice than in
tunicamycin-treated wild-type mice, indicating higher ATF4 activity in
the former group (Figure 3F and G). Of note, in contrast to Trb3
expression that was increased in PPARb/d-null mice compared to
wild-type mice, Chop expression was independent of the genotype and
it was only increased following tunicamycin treatment.
Since ER stress can also activate Nrf2 [33], we next evaluated whether
this antioxidant transcription factor can contribute to the increase
in VLDLR in tunicamycin-treated Pparb/d/ mice. Tunicamycin
administration led to signiﬁcant changes in hepatic phospho-Nrf2 and
NQO1 protein levels in wild-type mice, and the increase in phospho-
Nrf2 was exacerbated in Pparb/d-null mice (Figure 3H). Overall,
these ﬁndings suggest that ATF4 and Nrf2 activation by tunicamycin in
the presence of Pparb/d deﬁciency intensiﬁes the increase in hepatic
VLDLR.
3.3. FGF21 protects against hepatic steatosis and the upregulation
of VLDLR levels caused by ER stress
Since FGF21 suppresses the eIF2a-ATF4 pathway through a negative
feedback [34], we hypothesized that the reported increase in FGF21
observed in Pparb/d-deﬁcient mice [28] might attenuate the increase
in the ATF4-target gene Vldlr. To check this, we treated Pparb/d-null
mice with an FGF21 neutralizing antibody and tunicamycin. Adminis-
tration of the FGF21 neutralizing antibody to Pparb/d/ mice
increased hepatic triglyceride accumulation in both vehicle and
tunicamycin-treated mice compared with mice receiving IgG (Figure 4A
and B). Consistent with this, Vldlr mRNA levels increased in Pparb/d/
 mice injected FGF21 neutralizing antibody compared with mice
treated with IgG, especially in tunicamycin-treated mice (Figure 4C). No
changes in these parameters were observed in wild-type mice injected
with the neutralizing antibody (Figure S2A and B). VLDLR regulation by
FGF21 was conﬁrmed in the livers of Fgf21-deﬁcient mice. These mice
showed increased hepatic triglyceride accumulation (Figure 4D), a
process which has been reported to be age-dependent [35], and Vldlr
mRNA (Figure 4E) and protein abundance accompanied by enhanced
eIF2a phosphorylation and ATF4 protein levels (Figure 4F). Similarly,
the expression levels of two Atf4-target genes, Trb3 and Chop, were
also increased in the livers of Fgf21/ mice compared with wild-type
mice (Figure S2C and D), although Chop did not reach statistical sig-
niﬁcance. In contrast, phosphorylated levels of Nrf2 were reduced in
Fgf21/ mice (Figure 4G), rendering its involvement in VLDLR
upregulation unlikely. Finally, we examined the effects of recombinant
FGF21 treatment on ER-stress-induced VLDLR levels. In Huh-7 he-
patocytes FGF21 signiﬁcantly reduced the increase in VLDLR and
CHOP expression (Figure 5A and B) and in VLDLR protein levels caused122 MOLECULAR METABOLISM 8 (2018) 117e131  2017 The Authors. Published by Elsevier GmbH. Tby tunicamycin, and these reductions were accompanied by a
decrease in the levels of phospho-eIF2a (Figure 5C). Similarly,
administration of FGF21 reduced the increase in both the expression
and the protein levels of VLDR caused by tunicamycin in liver
(Figure 5D and E). These ﬁndings suggest that FGF21 may protect
against hepatic steatosis by limiting the increase in VLDLR levels via
attenuation of the eIF2a-ATF4 pathway.
3.4. VLDLR upregulation is intensiﬁed by fructose feeding in the
liver of Pparb/d-null mice
Fructose feeding leads to hepatic steatosis [36]. Consequently, we
explored whether VLDLR was involved in the effects of fructose on liver
in the context of Pparb/d deﬁciency. As previously shown [25], feeding
wild-type mice (C57BL/6X129/SV genetic background) with fructose
did not result in hepatic steatosis (Figure 6A and B). However, Pparb/
d/ mice exposed to fructose exhibited a clear and intense steatosis.
When hepatic VLDLR mRNA and protein levels were assessed, water-
fed Pparb/d/ mice showed a signiﬁcant increase that was inten-
siﬁed by fructose feeding (Figure 6C and D). As previously reported
[37], fructose feeding increased Fgf21 expression in liver of wild-type
mice (Figure S3A), indicating that despite the lack of induction of tri-
glyceride accumulation in the liver of wild-type mice, fructose feeding
was efﬁcacious. This increase was exacerbated in Pparb/d-deﬁcient
mice. In contrast, expression of the ATF4-target gene Chop was un-
affected in fructose-fed Pparb/d/ mice (Figure S3B), rendering it
unlikely that this pathway was involved in the VLDLR upregulation
observed in the liver of these mice. Consistent with the trend observed
in VLDLR, phospho-Nrf2 levels and the expression of its target gene
Nqo1 were elevated in livers of fructose-fed Pparb/d/ mice
(Figure 6E and F). The oxidative stress status measured by the lipid
peroxidized product MDA and H2O2 was signiﬁcantly increased only in
fructose-fed Pparb/d/ mice (Figure 6G and H), suggesting that
enhanced ROS levels was the stimulus responsible for the increase in
the activity of this redox transcription factor. To clearly demonstrate the
involvement of Nrf2, the expression of this gene and that of Pparb/
d was knocked down by siRNA transfection in mouse primary hepa-
tocytes. As previously shown, Pparb/d knockdown increased the
expression of Vldlr and this increase was intensiﬁed by incubation with
fructose (Figure 6I). However, Nrf2 knockdown abrogated the increase
caused by the reduction in Pparb/d expression and incubation with
fructose (Figure 6I). The increase in VLDLR expression was also
observed in human hepatocytes transfected with siRNA against
PPARb/d and this effect was speciﬁc for fructose, since it was not
observed in hepatocytes exposed to a related carbohydrate such as
mannitol (Figure S3C). Overall, these data suggest that in the context of
Pparb/d deﬁciency, fructose induces ROS production, a well-known
activator of Nrf2, which in turn increases VLDLR levels and ulti-
mately produces hepatic steatosis by increasing lipoprotein delivery to
the liver.
3.5. VLDLR content is increased in the liver of patients with
steatosis
Our ﬁndings in in vitro and animal models suggest a new potential
pathway that might contribute to NAFLD. In this pathway, a reduction in
PPARb/d levels might result in activation of both ATF4 and Nrf2, which
in turn would enhance VLDLR levels, leading to increased VLDL (tri-
glyceride) delivery to the liver. The contribution of this potential
pathway was explored in liver biopsies of patients classiﬁed into three
grades based on the percentage of hepatocytes presenting steatosis:
grade 0 (<5%), grade 2 or moderate steatosis (33e66%) and grade 3
or severe steatosis (>66%) (Figure 7A). VLDLR mRNA expressionhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Pparb/d deﬁciency exacerbates hepatic steatosis and VLDLR upregulation caused by ER stress. Oil Red O (A) and hematoxylin-eosin (B) staining of livers from
male wild-type (WT) and Pparb/d-null mice treated for 24 h through i.p. injection with DMSO (vehicle) or tunicamycin (Tunic) (3 mg kg1 body weight). Scale bar: 100 mm. C, Liver
triglyceride levels. D, Serum triglyceride levels. E, Immunoblot analyses of VLDLR. Trb3 (F) and Chop (G) mRNA abundance. H, immunoblot analyses of total and phospho-Nrf2 and
NQO1. Data are presented as the mean  S.D. (n ¼ 6 per group). ***p < 0.001, **p < 0.01 and *p < 0.05 vs. wild-type animals treated with DMSO (vehicle). ###p < 0.001,
##p < 0.01 and #p < 0.05 vs. wild-type animals treated with tunicamycin. yyyp < 0.001 and yp < 0.05 vs. Pparb/d-null mice treated with DMSO (vehicle).
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Figure 4: Increased Fgf21 expression in liver of Pparb/d-null mice attenuates VLDLR abundance. A, Oil Red O and hematoxylin-eosin staining of livers from male wild-type
(WT) and Pparb/d-null mice injected intraperitoneally with IgG (9 mg/mouse) or a neutralizing antibody (Ab) (9 mg/mouse) against FGF21 together with DMSO or tunicamycin (Tunic)
(3 mg kg1 body weight). Scale bar: 100 mm. Mice were sacriﬁced at 14 h after treatment. B, Liver triglyceride levels. C, Vldlr mRNA abundance. ***p < 0.001, **p < 0.01 and
*p< 0.05 vs. Pparb/d-null mice treated with IgG and DMSO. ##p< 0.01 and #p< 0.05 vs. Pparb/d-null mice treated with neutralizing antibody against FGF21 and DMSO. yp< 0.05
vs. Pparb/d-null mice treated with IgG and tunicamycin. Liver triglyceride levels (D) and Vldlr mRNA abundance (E) in the liver from WT and Fgf21/mice. Data are presented as the
mean  S.D. (n ¼ 5 per group). ***p < 0.001, **p < 0.01 and *p < 0.05 vs. wild-type mice. Immunoblot analyses of VLDLR, total and phospho-eIF2a and ATF4 (F) and total and
phospho-Nrf2 (G) were performed in liver lysates. Data are presented as the mean  S.D. (n ¼ 5 per group). ***p < 0.001, **p < 0.01 and *p < 0.05 vs. wild-type mice.
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Figure 5: Recombinant FGF21 protein attenuates the increase in VLDLR levels caused by ER stress. Human Huh-7 hepatocytes were incubated with DMSO (vehicle, control,
CT), tunicamycin (TUNIC) (1 mg/ml) or tunicamycin plus recombinant human FGF21 (1 mg/ml) and the mRNA abundance of VLDLR (A) and CHOP (B) and the protein levels of VLDLR
and total and phospho-eIF2a (C) were assessed (n ¼ 3 independent experiments). ***p < 0.001 vs. CT cells. #p < 0.05 vs. tunicamycin-treated cells. Analysis of the hepatic levels
of VLDLR in mice injected intraperitoneally with vehicle or recombinant mouse FGF21 together with DMSO or tunicamycin. Data are presented as the mean  S.D. (n ¼ 5 per
group). C, Vldlr and Chop mRNA abundance. D, Immunoblot analyses of hepatic VLDLR. ***p < 0.001, **p < 0.01 and *p < 0.05.(Figure 7B) and protein levels (Figure 7C) were increased in patients
suffering hepatic steatosis. The increase in VLDLR levels was
accompanied by a reduction in PPARb/d mRNA abundance that only
reached statistical signiﬁcance in livers of patients with severe hepatic
steatosis (Figure 7D). The expression of the PPARb/d-target genes
involved in fatty acid oxidation, PDK4 and CPT-1a, was reduced in the
livers of patients with steatosis (Figure 7D). Consistent with the
reduced levels of PPARb/d, the DNA-binding activity of this tran-
scription factor assessed by EMSA showed a reduction in patients with
hepatic steatosis, especially in those with severe hepatic steatosis
(Figure 7E). The reduction in PPARb/d expression and activity in pa-
tients with severe hepatic steatosis was accompanied by an increase
in HRI, TRB3, and NQO1 expression (Figure 7F), suggesting that theMOLECULAR METABOLISM 8 (2018) 117e131  2017 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comincrease in VLDLR levels in humans with severe hepatic steatosis in the
context of reduced PPARb/d levels might be the result of activation of
the HRI-eIF2a-ATF4 and Nrf2 pathways. Expression of ATF4-target
gene FGF21 was signiﬁcantly increased only in the patients with se-
vere steatosis (Figure 7G), whereas expression of its receptors,
b-klotho and FGFR1c, was reduced, although the reduction of the
receptor did not reach signiﬁcance, suggesting that the effect of this
hormone might be attenuated (Figure 7G).
4. DISCUSSION
Here we present evidence that VLDLR is regulated by PPARb/d and
FGF21. The reported increase in VLDLR in Pparb/d null macrophagesen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 125
Figure 6: VLDLR upregulation is intensiﬁed by fructose feeding in the liver of Pparb/d-null mice. Oil Red O (A) and hematoxylin-eosin (B) staining of livers from male wild-
type (WT) and Pparb/d-deﬁcient mice (PPARb/d/) fed with either water or water containing 30% fructose for eight weeks. Scale bar: 100 mm. C, Hepatic Vldlr mRNA abundance.
Immunoblot analyses of hepatic VLDLR (D) and total and phospho-Nrf2 (E). F, Nqo1 mRNA abundance. MDA (G) and H2O2 (H) levels from liver of wild-type (WT) and Pparb/d-
deﬁcient mice fed with either water or water containing 30% fructose. Data are presented as the mean  S.D. (n ¼ 6 per group). **p < 0.01 and *p < 0.05 vs. water-fed WT
mice. ##p < 0.01 and #p < 0.05 vs. fructose-fed WT mice. yyp < 0.01 and yp < 0.05 vs. water-fed Pparb/d/ mice. I, Vldlr mRNA abundance in primary hepatocytes transfected
with control, Ppard and Nrf2 siRNA for 24 h in the presence or absence of 25 mM fructose. *p < 0.05 vs. control siRNA. #p < 0.05 vs. Ppard siRNA.
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Figure 7: Liver of patients with steatosis show increased VLDLR content. A, Hematoxylin-eosin staining of liver biopsies from control subjects (Control, CT) and patients with
moderate (30e66% of hepatocytes presenting steatosis) and severe (>66%) hepatic steatosis. Scale bar: 100 mm. Hepatic VLDLR mRNA (B) and protein (C) abundance. D, mRNA
abundance of PPARb/d, PDK4 and CPT1a. E, autoradiograph of EMSA performed with a 32P-labeled PPRE and crude nuclear protein extract (NE) from liver biopsies. One main
speciﬁc complex (I) based on competition with a molar excess of unlabeled probe is shown. The supershift assay performed by incubating NE with an antibody (Ab) directed against
PPARb/d shows a reduction in the band. F, mRNA abundance of HRI, TRB3 and NQO1. G, mRNA abundance of FGF21, b-KLOTHO and FGFR1c. Data are presented as the
mean  S.D. (n ¼ 4 per group) relative to the control (CT) group. ***p < 0.001, **p < 0.01 and *p < 0.05 vs. CT group.
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Figure 8: Proposed mechanisms by which PPARb/d regulates VLDLR levels and hepatic steatosis. Pparb/d deﬁciency may result in an increase in VLDLR levels and hepatic
steatosis through several mechanisms. The activation of HRI caused by Pparb/d deﬁciency (reference [28]) and by activators of this kinase (BTdCPU) may increase the levels of
VLDLR through the eIF2a-ATF4 pathway. ER stress can also activate the eIF2a-ATF4 pathway leading to an increase in the expression of VLDLR and FGF21. This hormone
suppresses the eIF2a-ATF4 pathway through a negative feedback mechanism and thereby it also regulates the levels of VLDLR. ER stress also enhances the activity of Nrf2, a
transcription factor reported to upregulate the expression of Fgf21 (reference [19]). Fructose feeding increases the levels of ROS and the activity of Nrf2 providing a mechanism for
the increase of the levels of VLDLR. All these mechanisms may result in an increase in the levels of VLDLR causing hepatic steatosis. TG: triglyceride.
Original Article[38], prompted us to examine whether Pparb/d-null mice showed
increased VLDLR levels and determine its contribution to NAFLD and
the mechanisms involved. Our ﬁndings indicate that in Pparb/d-null
mice, HRI activation in liver increases VLDLR levels through the eIF2a-
ATF4 pathway (Figure 8). Despite this, HRI activators do not increase
hepatic steatosis; on the contrary, these compounds also increased
FGF21 levels and this hormonal factor improved glucose intolerance
and hepatic triglyceride accumulation induced by feeding a HFD [28].
In addition, Pparb/d-deﬁciency also results in the activation of Nrf2,
another transcription factor that contributes to increase VLDLR levels
[18]. Under conditions of Pparb/d-deﬁciency, the increase in VLDLR
levels would contribute to hepatic steatosis. In addition, stimulation of
ER stress induces hepatic steatosis through VLDLR [6], and this pro-
cess might be exacerbated in Pparb/d-null mice through a higher
activation of both ATF4 and Nrf2, suggesting that the absence of
PPARb/d contributes to intensify ER stress-induced fatty liver.
It has previously been reported that the PPARb/d agonist GW501516
promotes glucose ﬂux to the pentose phosphate pathway and fatty acid
synthesis in liver [39], establishing a discrepancy with the ﬁndings of
this manuscript. However, a time-course study demonstrated that
GW501516 induces accumulation of liver lipids following 4 wk of
treatment, but this turned into a reduction in the content of hepatic
lipids after 8 wk. of GW501516 treatment [40], probably as the result
of an increase in fatty acid oxidation. Therefore, long treatments with
GW501516 reduce hepatic lipids, which is consistent with the increase
in liver lipids observed in Pparb/d-null mice.
FGF21 has emerged as an important regulator of glucose and lipid
metabolism and hence is a promising agent for the treatment of
obesity, NAFLD, insulin resistance, and type 2 diabetes mellitus [41].
This study also suggests that the reported enhanced FGF21 levels in
Pparb/d-deﬁcient mice [28] prevent a higher increase in VLDLR levels128 MOLECULAR METABOLISM 8 (2018) 117e131  2017 The Authors. Published by Elsevier GmbH. Tand hepatic triglyceride accumulation. This effect of FGF21 is the result
of a negative feedback loop by which this hormone suppresses the
eIF2a-ATF4 pathway [28,34]. In fact, we show here that blocking
FGF21 increases VLDLR levels and hepatic steatosis. In agreement
with this, Fgf21/ mice showed increased hepatic activation of the
eIF2a-ATF4 pathway and VLDLR levels, suggesting that this receptor
may account for part of the hepatic steatosis observed in these mice.
Thus, FGF21 can prevent NAFLD by increasing hepatic fatty acid
oxidation and reducing lipid synthesis [41], and our ﬁndings indicate
that this hormone may also prevent NAFLD by downregulating VLDLR
levels.
Fructose feeding increases hepatic steatosis, but this process is
inﬂuenced by the genetic background of the mice. In our study, feeding
wild-type mice (C57BL/6X129/SV genetic background) with fructose
did not result in hepatic steatosis, although fructose feeding was
successful, as demonstrated by the increase in Fgf21 expression,
probably through carbohydrate response element binding protein
(ChREBP)-mediated mechanisms, as previously reported [37]. How-
ever, Pparb/d-null mice of the same genetic background fed with
fructose showed hepatic steatosis, and this was accompanied by
higher hepatic VLDLR levels. Our ﬁndings demonstrate that in the
context of Pparb/d deﬁciency, fructose induces ROS production,
leading to an increase in phospho-Nrf2 levels and therefore in its
activity. A step further, our siRNA studies demonstrated that this
transcription factor was responsible for fructose-induced Vldlr
expression in primary hepatocytes.
An analysis of human samples from patients with hepatic steatosis
showed an increase in the liver protein content of VLDLR compared
with control subjects. Interestingly, a reduction in PPARb/d levels and/
or activity, as demonstrated by EMSA and the expression of its target
genes, was also observed in the liver of these patients, suggesting thathis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the relationship between PPARb/d and VLDLR observed in mice might
also operate in humans with hepatic steatosis.
Targeting PPAR isotypes for the treatment of fatty liver disease has
been extensively studied, mainly in the case of PPARa [42,43].
However, although the beneﬁcial effect of activating PPARa for NAFLD
has been proven in several mouse models [42,43], ﬁbrates, which are
PPARa agonists, do not correct NAFLD in humans [44]. In contrast,
long-term activation of PPARb/d can improve hepatic steatosis by
activating fatty acid oxidation in different mouse models [45,46],
whereas clinical studies have also demonstrated a reduction of hepatic
fat content in humans upon treatment with PPARb/d agonists [47,48].
Our ﬁndings show that in patients with hepatic steatosis the reduction
in PPARb/d activity is accompanied by an increase in VLDLR levels. It
remains to be studied whether in the clinical setting PPARb/d agonists
improve hepatic steatosis by regulating VLDLR abundance. Moreover,
since we have reported that PPARb/d activation in mice increases
PPARa expression and activity and enhances the hepatic levels of the
endogenous PPARa ligand 16:0/18:1-phosphatidylcholine [49], we
cannot discard that the reduction of PPARb/d activity may also affect
the activity of PPARa. Consistent with this, drugs combining PPARa
and PPARb/d isotype agonism are a promising treatment for NAFLD. In
fact, the dual PPARa/b(d) agonist elaﬁbranor (GFT505) shows anti-
steaotic effects in rodent models [50], and, in abdominally obese
subjects, it improves hepatic and peripheral insulin sensitivity and
probably NAFLD, although liver fat content was not measured [51].
On the other hand, the increase in hepatic FGF21 expression in pa-
tients suffering hepatic steatosis is in agreement with previous studies
[52], and it has been considered to be the result of a resistance to this
hormone [53], implying that the lack of FGF21 activity may also
contribute to increase VLDLR levels in hepatic steatosis. It is important
to point out that the low number of patients analyzed is a limitation of
this part of the study and precludes that VLDLR plays a role in NAFLD
although it might correlate with liver fat accumulation.
5. CONCLUSIONS
The ﬁndings of this study suggest that Pparb/d-deﬁciency results in an
increase in VLDLR levels, whereas FGF21 prevents the increase in
hepatic VLDLR levels. In patients with hepatic steatosis, a reduction in
the levels and/or activity of PPARb/d was accompanied by an increase
in VLDLR abundance, suggesting that this crosstalk might be involved
in fatty liver development. Overall, these data suggest that modulation
of PPARb/d and/or FGF21 activity might be a key therapeutic target for
the treatment of hepatic steatosis by regulating VLDLR abundance.
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